Extracellular Vesicles and Their Applications in Tumor Diagnostics and Immunotherapy DOI Creative Commons
Scott Strum,

Valentina Evdokimova,

Laszlo Radvanyi

и другие.

Cells, Год журнала: 2024, Номер 13(23), С. 2031 - 2031

Опубликована: Дек. 9, 2024

Extracellular vesicles (EVs) are cell-derived nanoparticles that have attracted significant attention in the investigation of human health and disease, including cancer biology its clinical management. Concerning cancer, EVs been shown to influence numerous aspects oncogenesis, tumor proliferation metastasis. can augment immune system implicated virtually all innate adaptive immunity. With immunotherapy changing landscape treatment across multiple disease sites, it is paramount understand their mechanisms action further improve upon efficacy. Despite a rapidly growing body evidence supporting utility diagnostics therapeutics, application trials involving solid tumors remains limited. To date, relatively few known incorporate this context, mainly employing them as biomarkers. help address gap, review summarizes applications provides brief overview roles play biology, immunology, proposed implications immunotherapy. The impetus leverage future correlative studies crucial, they ideally positioned synergize with advancements multi-omics research therapeutic discovery our understanding biology.

Язык: Английский

Advancements in Colorectal Cancer Immunotherapy: From CAR-T Cells to Exosome-Based Therapies DOI

Sepideh Arabi,

Manouchehr Fadaee, Tohid Kazemi

и другие.

Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 23

Опубликована: Янв. 4, 2025

Colorectal cancer (CRC) continues to be a major worldwide health issue, with elevated death rates linked late stages of the illness. Immunotherapy has made significant progress in developing effective techniques improve immune system's capacity identify and eradicate cancerous cells. This study examines most recent advancements CAR-T cell treatment exosome-based immunotherapy for CRC. therapy, although treating blood cancers, encounters obstacles when used against solid tumors such as These include presence an immunosuppressive tumor microenvironment scarcity tumor-specific antigens. Nevertheless, novel strategies like dual-receptor cells combination therapy involving cytokines have demonstrated promise surmounting these obstacles. Exosome-based is promising approach targeted delivery therapeutic drugs cells, high specificity minimal off-target effects. However, there are still overcome field, resistance treatment, adverse effects associated system, necessity more individualized methods. The current research focused on enhancing therapies, results patients, ultimately incorporating innovative immunotherapeutic approaches into standard protocols

Язык: Английский

Процитировано

1

Cell-based Immunotherapy in Esophageal Cancer DOI
Masoud Lahouty,

Amirhossein Soleymanzadeh,

Sohrab Kazemi

и другие.

Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 19

Опубликована: Март 10, 2025

Esophageal cancer (EC) is among the most common illnesses globally, and its prognosis unfavorable. Surgery, radiotherapy, chemotherapy are primary therapy options for EC. Despite occasional efficacy of these traditional treatment modalities, individuals with EC remain at a significant risk local recurrence metastasis. Consequently, innovative efficacious medicines required. In recent decades, clinical practice has effectively implemented cell therapy, which includes both stem non-stem cell-based approaches, as an tumor treatment, offering renewed hope to patients esophageal squamous carcinoma (ESCC). This paper examines theoretical framework contemporary advancements in We further described current studies summarized essential data related survival safety assessments.

Язык: Английский

Процитировано

1

Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer DOI
Abdulmalik Saleh Alfawaz Altamimi, M. Arockia Babu, Muhammad Afzal

и другие.

Medical Oncology, Год журнала: 2025, Номер 42(4)

Опубликована: Март 18, 2025

Язык: Английский

Процитировано

0

Functional tumor-derived exosomes in NSCLC progression and clinical implications DOI Creative Commons
Yuxin Gao, Jun Xie,

Zhenya Yang

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 19, 2025

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases and remains one the leading causes cancer-related mortality worldwide. The high rate is primarily driven by delayed diagnosis, rapid metastasis, frequent recurrence. Tumor-derived exosomes (TEXs) have emerged as critical mediators in NSCLC progression, offering valuable insights into tumor microenvironment. Exosomes are small membrane vesicles that facilitate intercellular communication transport bioactive molecules, including proteins, RNAs, DNAs, thereby reflecting genetic complexity tumors. These play a key role promoting epithelial-mesenchymal transition (EMT), neovascularization, drug resistance, immune evasion, which pivotal development NSCLC. This review explores diverse roles TEXs focusing on their involvement pre-metastatic niche formation, tissue modulation. Specifically, we discuss exosome-associated RNAs proteins NSCLC, contribute to growth metastasis. Furthermore, explore potential biomarkers emphasizing application prognosis, prediction resistance targeted therapies immunotherapies.

Язык: Английский

Процитировано

0

Novel therapeutic approaches for non-small cell lung cancer: an updated view DOI

Niloufar Orooji,

Shabnam Babaei,

Manouchehr Fadaee

и другие.

Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 29

Опубликована: Апрель 5, 2025

Non-small cell lung cancer (NSCLC) continues to be one of the leading causes cancer-related mortality globally. Most patients who undergo surgical procedures may encounter distant metastasis or local recurrence, necessitating supplementary treatments such as radiation therapy, chemotherapy, targeted therapy adjuvant alternatives. Recent advancements in molecular biology and immunotherapy have paved way for innovative therapeutic approaches that target specific genetic mutations promote immune response against tumor cells. This review explores emerging therapies, including therapies tyrosine kinase inhibitors (TKIs) actionable (e.g., EGFR, ALK, ROS1), well role checkpoint (ICIs) employ body's system combat cancer. Additionally, we discuss potential exosome promising nanotherapeutic options treatment NSCLC. study attempts provide a thorough overview changing landscape NSCLC its implications enhancing patient outcomes by presenting these techniques.

Язык: Английский

Процитировано

0

Smart nanoparticle delivery of cancer vaccines enhances tumor immune responses: a review DOI Creative Commons
Jihua Qiu,

Chenghu Wu

Frontiers in Nanotechnology, Год журнала: 2025, Номер 7

Опубликована: Апрель 14, 2025

Cancer arises from the uncontrolled proliferation of tumor cells within body. As incidence cancer continues to rise, its treatment has become a critical focus for clinicians. The body possesses immune surveillance mechanism designed inhibit cells. When tumor-associated mutant antigens appear on cell surface, antigen-presenting cells, as dendritic present these specific such T lymphocytes, thereby promoting an response and enhancing cytotoxic effect Concurrently, system develops memory, akin elicited by vaccination. While traditional diseases like tuberculosis tetanus can be prevented treated through vaccination, development vaccines remains in nascent stages. Tumor-specific originate patient’s own or generated mutation. Thus, presentation tumor-specific is pivotal anti-tumor immunotherapy. Advances nanoscience offer novel approaches Nanoparticles (NPs) engineered nanotechnology have garnered significant attention due their diverse, favorable, stable properties. These NPs effectively encapsulate chemotherapy drugs proteins, facilitating targeted delivery vivo . Common carriers include liposomes, polymeric nanoparticles, metal among others. intelligent systems enhance efficient antigen presentation, augmenting responses. sourced In this review, we summarize current methodologies obtaining various discuss how delivered via different bolster immunity. Additionally, clinical translation perspective, explore challenges opportunities associated with responses smart NP vaccines. We aim review inspire new strategies use advance research

Язык: Английский

Процитировано

0

Exosome-driven nano-immunotherapy: revolutionizing colorectal cancer treatment DOI
Masoud Lahouty, Manouchehr Fadaee, Dariush Shanehbandi

и другие.

Molecular Biology Reports, Год журнала: 2024, Номер 52(1)

Опубликована: Дек. 26, 2024

Язык: Английский

Процитировано

3

Extracellular Vesicles and Their Applications in Tumor Diagnostics and Immunotherapy DOI Creative Commons
Scott Strum,

Valentina Evdokimova,

Laszlo Radvanyi

и другие.

Cells, Год журнала: 2024, Номер 13(23), С. 2031 - 2031

Опубликована: Дек. 9, 2024

Extracellular vesicles (EVs) are cell-derived nanoparticles that have attracted significant attention in the investigation of human health and disease, including cancer biology its clinical management. Concerning cancer, EVs been shown to influence numerous aspects oncogenesis, tumor proliferation metastasis. can augment immune system implicated virtually all innate adaptive immunity. With immunotherapy changing landscape treatment across multiple disease sites, it is paramount understand their mechanisms action further improve upon efficacy. Despite a rapidly growing body evidence supporting utility diagnostics therapeutics, application trials involving solid tumors remains limited. To date, relatively few known incorporate this context, mainly employing them as biomarkers. help address gap, review summarizes applications provides brief overview roles play biology, immunology, proposed implications immunotherapy. The impetus leverage future correlative studies crucial, they ideally positioned synergize with advancements multi-omics research therapeutic discovery our understanding biology.

Язык: Английский

Процитировано

0